ROCKVILLE, Md.--(BUSINESS WIRE)-- Rexahn Pharmaceuticals, Inc. (NYSE Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it will present at Needham & Company’s 10th Annual Healthcare Conference on Wednesday, April 6, 2011, at 2:40 p.m. EDT in New York City.
Rexahn’s President and Chief Operating Officer, Rick Soni, and Chief Financial Officer, Ted Jeong, will provide a strategic business overview of the Company, including a discussion of its R&D pipeline. Presentation materials from the conference will be available in the Investor Relations section of the Company’s website, www.rexahn.com.
About Rexahn Pharmaceuticals, Inc.
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to developing and commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials, Archexin®, Serdaxin®, and Zoraxel™ - all potential best in class therapeutics - and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also operates key R&D programs of nano-medicines, 3D-GOLD, and TIMES drug discovery platforms. For more information, please visit www.rexahn.com.
Rexahn Pharmaceuticals, Inc.
Stern Investor Relations, Inc.
Stephanie Ascher, 212-362-1200
Base Pair Communications
Constantine Theodoropulos, 617-401-3116
KEYWORDS: United States North America Maryland New York
INDUSTRY KEYWORDS: Health Biotechnology Oncology Pharmaceutical General Health